Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
$13.16
$0.01(0.11%)
At close: 4:00 PM EST
$13.16
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $14.91
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.07M
Market Cap
$935.35M
Enterprise Value$424.09M
Total Cash (Recent Filing)$255.73M
Total Debt (Recent Filing)$21.82M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Oct 29, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding68,927,420
10 Day Avg. Volume1,289,836
30 Day Avg. Volume1,066,744
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.25
Price to Sales (P/S)9.69
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue8.17
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda-2.40
Forecast
1Y Price Target
$33.00Price Target Upside150.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PositionEYPT is trading at a heavy discount compared to its competitor OCUL, creating a lucrative buying opportunity.
Product ApprovalEYPT finds itself in the pole position with respect to when the first TKI-based product for wAMD might get approved.
Product LaunchDuravyu is prepared to launch immediately following a potential approval by the end of 2027, making it the first long-acting TKI to reach market with a differentiated Q6M label.
Bears Say
RisksRisks include, but are not limited to: failure of DURAVYU in clinical trials, failure to obtain regulatory approval, failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.
Value PropositionDeclining rescue-free rates could dent the value proposition of a one-and-done therapy, as patients would anyway need to come in regularly for monitoring, perhaps more frequently with passing time.
EyePoint Pharmaceuticals News
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $3.91 and its highest was $14.91 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $935.35M.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2025 which is in 14 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Aug 06, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.823 by -$0.027.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.77.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 68,927,420 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.823. Following the earnings report the stock price went down -2.847%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (150.76% Upside)
$33.00 (150.76% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.07%
12-Months-Change
Fundamentals
Return on Equity
-73.95%
Trailing 12-Months
Asset Growth
-7.12%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in sustained-release drug delivery systems to treat chronic ocular conditions, particularly in the areas of retinal diseases, glaucoma, and ocular inflammation. EyePoint's core products include Yutiq, an implant for the treatment of non-infectious uveitis, and Dextenza, a dissolvable insert for the treatment of post-surgical pain and inflammation.
EYPT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
EyePoint announced significant progress in clinical trials and financial stability, highlighted by the rapid Phase III enrollment for DURAVYU and a strong cash position. However, the company also faced challenges with decreased revenue, increased operating expenses, and a higher net loss. The sentiment of the call reflects optimism about future milestones and the potential market position, but acknowledges the current financial strains due to increased investments in clinical trials.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$33.00
▲(150.76% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
0.89% Insiders
18.62% Mutual Funds
49.50% Other Institutional Investors
20.57% Public Companies and
Individual Investors